Rani Therapeutics Holdings, Inc. and PegBio Co., Ltd. have formed a research and development collaboration to evaluate whether several injectable obesity and metabolic disease candidates can be delivered through Rani Therapeutics’ swallowable RaniPill platform. The partners plan to screen oral formulations, complete preclinical development and select the most promising programmes for possible advancement into human trials.
The collaboration gives PegBio a route to develop alternative formulations for a metabolic pipeline that includes dual and triple receptor agonists, while Rani Therapeutics gains access to multiple molecules rather than a single experimental payload. It also strengthens Rani Therapeutics’ effort to position its capsule as a platform that can support several obesity mechanisms instead of functioning as a delivery system tied to one GLP-1 medicine.
The announcement nevertheless represents the beginning of an evaluation process, not a completed licensing transaction. PegBio disclosed that the companies signed a three-year memorandum of understanding and have not yet entered formal research, licensing, manufacturing or commercialisation agreements for any named candidate. Future arrangements will depend on whether preclinical studies produce acceptable oral delivery, pharmacokinetic and pharmacodynamic results.
What have Rani Therapeutics and PegBio actually agreed to develop under the new collaboration?
The partners will select multiple molecules from PegBio’s obesity and metabolic disease portfolio and assess whether they can be formulated for delivery through the RaniPill capsule. Their immediate work will remain preclinical, covering formulation screening and the studies needed to decide whether any programme is suitable for clinical development.
The arrangement is broader than a conventional one-asset formulation project. PegBio said the evaluation may cover multi-target metabolic modulators, long-acting platform assets and other innovative programmes with differentiated mechanisms.
That breadth could allow the companies to compare how different molecular sizes, dose requirements and pharmacological properties perform using the same oral delivery technology. One candidate may provide better bioavailability, another may be easier to manufacture and a third may show a more attractive dosing profile.
No specific molecule has been publicly assigned to the collaboration. The companies have also not disclosed financial terms, responsibility for research spending, ownership of newly generated intellectual property or how future development costs would be divided.
PegBio’s regulatory announcement makes the uncertainty explicit. Any co-development, regional licensing, manufacturing or commercialisation arrangement will require additional negotiations and formal contracts. Investors should therefore view the current collaboration as an option-creating framework rather than a transaction that already carries committed milestone payments or defined product rights.
Why is turning an injectable obesity biologic into an oral treatment technically difficult?
Large biological molecules generally cannot be converted into tablets through ordinary pharmaceutical formulation. Proteins and peptides can be degraded by stomach acid and digestive enzymes, while their size makes it difficult for them to cross the intestinal lining and enter systemic circulation in therapeutically useful amounts.
Rani Therapeutics is attempting to avoid those limitations rather than solve them through conventional intestinal absorption. The RaniPill capsule is designed to pass through the stomach, activate in the small intestine and deliver its payload through the highly vascularised intestinal wall. The company describes the device as a swallowable auto-injector intended to produce exposure comparable with a subcutaneous injection.
The approach could be particularly relevant in obesity and other chronic metabolic diseases because patients may remain on treatment for years. A capsule could remove the need for patients to handle needles, store injection devices or follow injection routines.
Convenience alone will not establish clinical value. The system must deliver a reliable dose across patients with different gastrointestinal conditions, diets, body sizes and intestinal transit times. It must also function safely after repeated administration, potentially weekly or more frequently depending on the candidate.
Payload capacity may become another constraint. Some long-acting metabolic medicines require doses that may be more challenging to accommodate than highly potent biologics administered in small quantities. The selected PegBio molecules will therefore need to match the capsule’s technical limits as well as its biological capabilities.
The comparison will not simply be oral treatment versus injection. The partners must determine whether the oral product can preserve the drug’s efficacy, tolerability and dosing consistency without introducing device-related risks or excessive manufacturing costs.
Which parts of PegBio’s metabolic portfolio could offer the strongest development fit?
PegBio has not identified the molecules selected for the collaboration, making it inappropriate to assume that any named asset is already being reformulated. Its pipeline nevertheless illustrates the types of programmes that could be considered.
The company’s clinical-stage PB-718 is a long-acting GLP-1 and glucagon dual receptor agonist being developed for obesity and metabolic dysfunction-associated steatohepatitis. PegBio completed a Phase 1 trial in healthy participants in the United States and a Phase 1b/2a study in people with obesity in China. The company reported preliminary efficacy signals and an improvement trend in liver fat, while continuing to evaluate the programme’s later development strategy.
PegBio also has earlier-stage multi-receptor programmes. PB-2309 is a preclinical GLP-1, GIP and glucagon triple receptor agonist intended for type 2 diabetes, obesity and metabolic liver disease. PB-2301 is another preclinical candidate being evaluated across similar metabolic indications.
Its commercial-stage PB-119, or visepegenatide injection, is a long-acting GLP-1 receptor agonist that received Chinese marketing approval in November 2025. PegBio has been preparing commercial production, supply and market access for the medicine, although its public materials do not indicate that PB-119 is included in the Rani Therapeutics work.
The more likely selection logic will consider dose size, molecular stability, expected treatment frequency and whether an oral version would meaningfully differentiate the asset. A molecule already optimised for infrequent injections may deliver less convenience advantage than one requiring more regular administration.
PegBio must also decide whether oral formulation work could delay its existing injectable programmes. Developing two dosage forms can increase intellectual property value and market coverage, but it can also divide capital and management attention.
How does the PegBio agreement expand Rani Therapeutics’ existing obesity strategy?
Rani Therapeutics already has an obesity programme in human testing through its collaboration with ProGen Co., Ltd. RT-114 combines the RaniPill capsule with PG-102, a GLP-1 and GLP-2 dual agonist, and entered Phase 1 development in January 2026.
That trial is evaluating safety, tolerability, bioavailability, pharmacokinetics and weight-loss effects after single and multiple oral doses compared with subcutaneous administration. Rani Therapeutics previously reported that preclinical delivery of PG-102 produced exposure and weight-loss effects comparable with injection.
The company has separately evaluated oral delivery of semaglutide in animals and reported comparable pharmacokinetics, bioavailability and weight-loss activity relative to subcutaneous administration. The new PegBio collaboration could add multiple mechanisms beyond these existing programmes, reducing dependence on any one molecule.
Rani Therapeutics describes its platform as payload-agnostic and says it has generated clinical proof of concept across 19 biologic molecules. According to the company, 233 capsules have been administered to 146 human participants, with injectable-like bioavailability and no serious adverse events reported in those studies. These figures remain company-reported and do not establish that every new payload will perform comparably.
The PegBio work is strategically useful because platform companies gain credibility when unrelated partners commit multiple assets to their technology. One successful candidate could validate a specific product. Several successful candidates with different mechanisms would provide stronger evidence that the delivery system can support a repeatable development model.
Which preclinical results will decide whether any candidate can enter human testing?
The first hurdle will be reliable capsule deployment. Researchers must demonstrate that the system consistently reaches the intended intestinal location, activates correctly and delivers the required amount of medicine without meaningful variability.
Pharmacokinetic testing will assess whether the oral product produces adequate drug exposure and whether that exposure is comparable with the injectable formulation. Large differences between patients could make dose selection difficult even when average bioavailability appears acceptable.
Pharmacodynamic studies must then show that successful delivery produces the intended biological effects. For metabolic candidates, investigators may monitor glucose regulation, appetite-related signals, body weight, liver fat and other mechanism-specific markers.
Repeat-dose safety will be essential because obesity treatments are not one-time interventions. The companies will need evidence that regular use does not create gastrointestinal injury, inflammation, capsule retention or other complications that become visible only after repeated administration.
The payload itself must also remain stable during manufacturing, storage, swallowing and transit through the stomach. Delivering a molecule successfully once in a controlled study is different from producing thousands or millions of capsules with consistent performance.
Manufacturing economics will influence candidate selection before clinical development begins. An oral product that requires expensive device components or has low production yields could struggle commercially, particularly in an obesity market where payers are already scrutinising treatment costs.
Could the memorandum eventually become a licensing and commercialisation deal outside China?
PegBio said positive preclinical results could lead the companies to consider clinical development, co-development, regional licensing, manufacturing and commercialisation arrangements for markets outside China. The current memorandum therefore creates several possible deal structures without committing the parties to one model.
PegBio could retain rights in China while granting Rani Therapeutics or another partner rights elsewhere. The companies might also divide development responsibilities, with PegBio supplying the active molecule and Rani Therapeutics manufacturing the delivery capsule.
A successful oral formulation could increase the transaction value of a PegBio asset. Pharmaceutical companies interested in metabolic medicines may view an injectable and oral development pathway as more attractive than a molecule restricted to one route of administration.
For Rani Therapeutics, a formal agreement could generate research funding, licence payments, milestones, manufacturing revenue or royalties. The company’s existing collaboration with Chugai Pharmaceutical has already begun contributing contract revenue, demonstrating that platform partnerships can provide non-dilutive funding before product approval.
Rani Therapeutics reported $43.4 million in cash, cash equivalents and marketable securities at March 31, 2026. It expected those resources, including an anticipated Chugai technology-transfer milestone, to fund operations into the fourth quarter of 2027. The PegBio memorandum did not include a disclosed upfront payment that would extend that runway.
The absence of financial terms is important. The agreement could ultimately become a valuable partnership, but it currently adds development opportunity rather than recognised revenue or guaranteed funding.
Why did PegBio shares surge while Rani Therapeutics received a muted market response?
PegBio shares closed at HK$7.13 on July 10, rising 28.93 percent during the session. Trading volume reached approximately 141.4 million shares, far above the reported average of around 18.6 million, indicating unusually strong investor interest in the collaboration.
The reaction suggests that investors attributed meaningful optionality to the possibility of oral formulations and future overseas deals. PegBio’s announcement emphasised that the partnership could increase the global development and potential transaction value of several metabolic assets.
The rally should be interpreted against considerable volatility. PegBio’s shares remained far below their 52-week high of HK$77, while the reported 52-week low was HK$4.94. A sharp percentage gain from a depressed base does not mean the market has assigned full commercial value to the oral programmes.
Rani Therapeutics shares traded near $0.69 at the end of July 10 and changed little during the session. The stock remained substantially below its 52-week high of $3.87, indicating that investors continue to demand stronger clinical and commercial evidence from the platform.
The contrast is revealing. For PegBio, the collaboration introduced a new formulation strategy and international development route across several assets. For Rani Therapeutics, it added another early-stage partner to a platform whose value still depends on successful clinical delivery, manufacturing scale and deal economics.
What developments would turn this early collaboration into a material clinical programme?
The first meaningful update would be disclosure of the selected PegBio candidates. Naming the molecules would allow investors and clinicians to assess dose requirements, mechanism, development stage and the likely value of an oral formulation.
Preclinical pharmacokinetic and pharmacodynamic results will provide the next test. Comparable exposure to injection would support continued investment, while inconsistent delivery or inadequate dose capacity could eliminate programmes before clinical development.
A formal agreement would represent a separate commercial milestone. Financial terms, regional rights and responsibility for manufacturing would reveal how the companies divide risk and how much value Rani Therapeutics can capture from the platform.
The eventual initiation of a human trial would move the collaboration beyond formulation research. Even then, the partners would need to show reliable repeat dosing and clinically meaningful metabolic effects rather than simply demonstrating that the capsule can deliver measurable drug concentrations.
PegBio’s share-price surge shows why oral obesity medicines command intense attention. The collaboration offers a credible scientific route toward removing injections from several metabolic programmes, but it has not yet produced a clinical candidate, a licensing payment or a committed development schedule.
The opportunity rests on a straightforward but demanding test: whether the RaniPill can turn PegBio’s differentiated molecules into dependable oral medicines without sacrificing the exposure, efficacy and safety achieved by injection. The next data, rather than the memorandum itself, will determine whether that promise becomes a new product pathway or remains one more experiment in the crowded race to make biologic obesity treatment easier to take.
